Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELA: T-DM1 + Lapatinib + Abraxane in Metastatic HER2+ Breast Cancer
NCT02073916Phase 1Completed
- Start
- Oct 2013
- Primary completion
- Dec 2018
- Modality
- Polymer-based Nanoparticles, Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab emtansine, lapatinib and nab-paclitaxel in breast cancer. Primary endpoint: Maximum Tolerable Dose at 16 weeks. Started Oct 2013; status: completed.
02
Drugs
trastuzumab emtansinelapatinibnab-paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02073916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02073916.